Letsure 5 Tablet contains Letrozole 5mg, a non-steroidal aromatase inhibitor used primarily in the treatment of hormone receptor-positive breast cancer in postmenopausal women. Letrozole works by inhibiting the aromatase enzyme, which is responsible for converting androgens to estrogens, thereby reducing estrogen levels in the body. This reduction in estrogen helps slow or stop the growth of estrogen-dependent breast cancer cells. Letsure 5 is indicated for adjuvant treatment of early breast cancer, extended adjuvant treatment following tamoxifen therapy, and for advanced or metastatic breast cancer. The tablet is administered orally, typically once daily, with or without food, as prescribed by a healthcare professional. Common side effects may include hot flashes, joint pain, fatigue, and increased sweating, while less frequent adverse effects can involve bone density loss, necessitating monitoring during prolonged therapy. Contraindications include hypersensitivity to Letrozole or any excipients and use in premenopausal women due to the risk of ovarian stimulation. Patients should inform their physician about any concurrent medications or medical conditions before initiating treatment. Letsure 5 Tablet should be used under strict medical supervision to ensure optimal therapeutic outcomes and minimize potential risks.